Literature DB >> 26408331

Overexpression of CDT1 Is a Predictor of Poor Survival in Patients with Hepatocellular Carcinoma.

Dimitrios Karavias1, Ioannis Maroulis2, Helen Papadaki3, Charalambos Gogos4, Stavros Kakkos5, Dionissios Karavias2, Vasiliki Bravou3.   

Abstract

BACKGROUND: Genomic instability is a common feature in hepatocellular carcinoma. Deregulation of replication licensing factors has been shown to trigger DNA damage response contributing to genomic instability. Overexpression of DNA replication licensing factors chromatin licensing and DNA replication factor 1 (CDT1) and minichromosome maintenance complex component 7 (MCM7) has been previously reported in several human cancers. The aim of the present study was to evaluate the expression and prognostic significance of CDT1 and MCM7 in association with DNA damage response markers and p53 in patients with hepatocellular carcinoma.
METHODS: Expression of CDT1, MCM7, p-H2A histone family member X (H2AX), phospho-ataxia telangiectasia-mutated (ATM)/ataxia telangiectasia rad3-related (ATR) substrate, and p53 was evaluated by immunohistochemistry on formalin-fixed paraffin-embedded surgical specimens from 111 patients who underwent hepatectomy for hepatocellular carcinoma. Statistical analysis was performed to evaluate associations between the studied proteins, clinicopathological parameters, and patient survival.
RESULTS: CDT1 expression correlated with p-H2AX (p = 0.038), while MCM7 correlated with p-H2AX and phospho-ATM/ATR substrate (p < 0.001). Increased CDT1 expression was associated with higher tumor grade (p = 0.006) and tumor-node-metastasis (TNM) stage (p = 0.033). High CDT1 expression correlated significantly with reduced overall survival (60.8 and 26.5 % vs 82.8 and 53.0 %, for low CDT1 expression, at 2 and 5 years, respectively, p = 0.012) and was identified by multivariate analysis as an independent predictor of poor overall survival (p = 0.049).
CONCLUSIONS: Overexpression of CDT1 and MCM7 in hepatocellular carcinoma correlates with DNA damage response, and CDT1 overexpression is a significant prognostic biomarker in hepatocellular carcinoma.

Entities:  

Keywords:  CDT1; Hepatocellular carcinoma; MCM7

Mesh:

Substances:

Year:  2015        PMID: 26408331     DOI: 10.1007/s11605-015-2960-7

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  38 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.

Authors:  Jirina Bartkova; Zuzana Horejsí; Karen Koed; Alwin Krämer; Frederic Tort; Karsten Zieger; Per Guldberg; Maxwell Sehested; Jahn M Nesland; Claudia Lukas; Torben Ørntoft; Jiri Lukas; Jiri Bartek
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

3.  MCM7 expression predicts post-operative prognosis for hepatocellular carcinoma.

Authors:  Yan-Ming Zhou; Xiao-Feng Zhang; Lu Cao; Bin Li; Cheng-Jun Sui; Yu-Min Li; Zheng-Feng Yin
Journal:  Liver Int       Date:  2012-07-12       Impact factor: 5.828

4.  A p53-dependent checkpoint pathway prevents rereplication.

Authors:  Cyrus Vaziri; Sandeep Saxena; Yesu Jeon; Charles Lee; Kazutaka Murata; Yuichi Machida; Nikhil Wagle; Deog Su Hwang; Anindya Dutta
Journal:  Mol Cell       Date:  2003-04       Impact factor: 17.970

Review 5.  Apoptosis and autophagy: Regulation of apoptosis by DNA damage signalling - roles of p53, p73 and HIPK2.

Authors:  Nadja Bitomsky; Thomas G Hofmann
Journal:  FEBS J       Date:  2009-09-29       Impact factor: 5.542

6.  Overexpression of the replication licensing regulators hCdt1 and hCdc6 characterizes a subset of non-small-cell lung carcinomas: synergistic effect with mutant p53 on tumor growth and chromosomal instability--evidence of E2F-1 transcriptional control over hCdt1.

Authors:  Panagiotis Karakaidos; Stavros Taraviras; Leandros V Vassiliou; Panayotis Zacharatos; Nikolaos G Kastrinakis; Dionysia Kougiou; Mirsini Kouloukoussa; Hideo Nishitani; Athanasios G Papavassiliou; Zoi Lygerou; Vassilis G Gorgoulis
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 7.  Control of DNA replication licensing in a cell cycle.

Authors:  Hideo Nishitani; Zoi Lygerou
Journal:  Genes Cells       Date:  2002-06       Impact factor: 1.891

8.  Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis.

Authors:  K A Honeycutt; Z Chen; M I Koster; M Miers; J Nuchtern; J Hicks; D R Roop; J M Shohet
Journal:  Oncogene       Date:  2006-03-06       Impact factor: 9.867

9.  Hepatitis B virus X protein via the p38MAPK pathway induces E2F1 release and ATR kinase activation mediating p53 apoptosis.

Authors:  Wen-Horng Wang; Ronald L Hullinger; Ourania M Andrisani
Journal:  J Biol Chem       Date:  2008-07-07       Impact factor: 5.157

Review 10.  Involvement of DNA damage response pathways in hepatocellular carcinoma.

Authors:  Sheau-Fang Yang; Chien-Wei Chang; Ren-Jie Wei; Yow-Ling Shiue; Shen-Nien Wang; Yao-Tsung Yeh
Journal:  Biomed Res Int       Date:  2014-04-28       Impact factor: 3.411

View more
  17 in total

1.  Integrin-Linked-Kinase Overexpression Is Implicated in Mechanisms of Genomic Instability in Human Colorectal Cancer.

Authors:  Panagiota Chadla; Marina Arbi; Sofia Nikou; Theodoros Kalliakoudas; Helen Papadaki; Stavros Taraviras; Zoi Lygerou; Vasiliki Bravou
Journal:  Dig Dis Sci       Date:  2020-06-03       Impact factor: 3.199

Review 2.  Strategic role of the ubiquitin-dependent segregase p97 (VCP or Cdc48) in DNA replication.

Authors:  Kristijan Ramadan; Swagata Halder; Katherine Wiseman; Bruno Vaz
Journal:  Chromosoma       Date:  2016-04-18       Impact factor: 4.316

3.  ILK Expression in Colorectal Cancer Is Associated with EMT, Cancer Stem Cell Markers and Chemoresistance.

Authors:  Dimitrios Tsoumas; Sofia Nikou; Efstathia Giannopoulou; Spyridon Champeris Tsaniras; Chaido Sirinian; Ioannis Maroulis; Stavros Taraviras; Vassiliki Zolota; Haralabos P Kalofonos; Vasiliki Bravou
Journal:  Cancer Genomics Proteomics       Date:  2018 Mar-Apr       Impact factor: 4.069

4.  Five Novel Oncogenic Signatures Could Be Utilized as AFP-Related Diagnostic Biomarkers for Hepatocellular Carcinoma Based on Next-Generation Sequencing.

Authors:  Zheng Yu; Rongchang Wang; Fan Chen; Jianru Wang; Xiaohui Huang
Journal:  Dig Dis Sci       Date:  2018-02-13       Impact factor: 3.199

5.  LIMK/cofilin pathway and Slingshot are implicated in human colorectal cancer progression and chemoresistance.

Authors:  Helen Aggelou; Panagiota Chadla; Sofia Nikou; Sofia Karteri; Ioannis Maroulis; Haralabos P Kalofonos; Helen Papadaki; Vasiliki Bravou
Journal:  Virchows Arch       Date:  2018-01-19       Impact factor: 4.064

6.  miR-221-3p promotes hepatocellular carcinogenesis by downregulating O6-methylguanine-DNA methyltransferase.

Authors:  Zushun Chen; Bangde Xiang; Lunan Qi; Shaoliang Zhu; Lequn Li
Journal:  Cancer Biol Ther       Date:  2020-10-06       Impact factor: 4.742

7.  TGFβ1 Cell Cycle Arrest Is Mediated by Inhibition of MCM Assembly in Rb-Deficient Conditions.

Authors:  Brook S Nepon-Sixt; Mark G Alexandrow
Journal:  Mol Cancer Res       Date:  2018-09-26       Impact factor: 5.852

8.  The prognostic significance of Cdc6 and Cdt1 in breast cancer.

Authors:  Ravikiran Mahadevappa; Henrique Neves; Shun Ming Yuen; Yuchen Bai; Cian M McCrudden; Hiu Fung Yuen; Qing Wen; Shu Dong Zhang; Hang Fai Kwok
Journal:  Sci Rep       Date:  2017-04-20       Impact factor: 4.379

Review 9.  Regulation and Function of Cdt1; A Key Factor in Cell Proliferation and Genome Stability.

Authors:  Pedro N Pozo; Jeanette Gowen Cook
Journal:  Genes (Basel)       Date:  2016-12-22       Impact factor: 4.096

10.  miR-221 suppression through nanoparticle-based miRNA delivery system for hepatocellular carcinoma therapy and its diagnosis as a potential biomarker.

Authors:  Feng Li; Feiran Wang; Changlai Zhu; Qun Wei; Tianyi Zhang; You Lang Zhou
Journal:  Int J Nanomedicine       Date:  2018-04-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.